Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection

Antiviral Therapy

Volumn 7, Issue 3, 2002, Pages 199-209

  Wheat, L Joseph ^a   Farthing, Charles ^b   Cohen, Calvin ^c   Pierone, Gerald ^d   Lalezari, Jay ^e   Pilson, Robert S ^f   Siemon Hryczyk, Peggy ^f  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AIDS HEALTHCARE FOUNDATION   (United States)

^c Community Research Initiative ^*  (United States)

^d Treasure Coast Infectious Disease Consultants   (United States)

^e Quest Clinical Research   (United States)

^f HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; GELATIN; LAMIVUDINE; LIPID; NELFINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOFT GELATIN CAPSULE; VIRUS TITRATION; VOMITING;

ADULT; CAPSULES; CD4 LYMPHOCYTE COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIPIDS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RNA, VIRAL; SAQUINAVIR;

EID: 0036768334     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ & Holmberg SD. Declining morbidity, and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 1998; 338:853-860.
2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d'Arminio Monforte A, Yust I, Bruun JN, Phillips AN & Lundgren JD. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352:1725-1730.
3. Paterson D, Swindells S, Mohr J, Brester M, Vergis E, Squier C, Wagener M & Singh N. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMSCaps. 6th International Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, 31 January-4 Februay 1999, Abstract 92.
4. Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, Johnson D, Dube MP, Hwang JY & McCutchan JA. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999; 13:1099-1107.
5. Carpenter CCJ, Cooper DA, Fischl AM, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG & Volberding PA. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 2000; 283:381-390.
6. Greenberg RN. Overview of patient compliance with medication dosing: a literature overview. Clinical Therapeutics 1984; 6:592-599.
7. Bradley C. Compliance with drug therapy. Prescribers' Journal 1999; 39:4551.
8. Andrejak M, Genes N, Vaur L, Poncelet P, Clerson P & Carre A. Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once daily versus twice daily regimen. American Journal of Hypertension 2000; 12:184-190.
9. Eldred LJ, Wu AW, Chaisson RE & Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 1998; 18:117-125.
10. Stellbrink H-J, Hawkins DA, Clumeck N, Cooper DA, Myers R Jr, Delfraissy J-F, John Gill M, Ramirez-Ronda C, Vella S, Salgo M & Bragman K. Randomised, multicentre phase III study of saquinavir plus zidovudine plus zalcitabine in previously untreated or minimally pretreated HIV-infected patients. Clinical Drug Investigation 2000; 20:295-307.
11. Tsoukas C, on behalf of the nNV15355 study group. Predictive Value of Response at 12 and 24 Weeks for Durability of Response in a Study of the Soft Gelatin Capsule Formulation of Saquinavir (SQV-SGC) plus 2 Nucleosides in Treatment-Naive HIV-1-Positive Patients. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, 31 January to 4 February 1999, Abstract and poster 165.
12. Gill MJ & the NV15182 Study Team. Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. AIDS 1998; 12:1400-1402.
13. Cohen-Stuart JWT, Schuurman R, Burger DM, Koopmans PP, Sprenger HG, Juttmann JR, Richter C, Meenhorst PL, Hoetelmans RM, Kroon FP, Bravenboer B, Hamann D, Boucher CA & Borleffs JC. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study). AIDS 1999; 13:F53-F58.
14. Moyle G, Pozniak A, Opravil M, Clumeck N, DelFraissy JF, Johnson M, Pelgrom J, Reynes J, Vittecoq D, DeLora P, Salgo M, Duff F. The SPICE study: 48-week activity of combination of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Journal of Acquired Immune Deficiency Syndrome 2000; 23:128-137.
15. Mitsuyasu RT, Skolnik PR, Cohen SR, Conway B, Gill MJ, Jensen PC, Pulvirenti JJ, Slater LN, Schooley RT, Thompson MA, Torres RA & Tsoukas CM. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naïve patients. AIDS 1998; 12:F103-F109.
16. Lalezari J, on behalf of the NV15107 Study Group. Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 1998; 19:195-197.
17. Gieschke R, Fotteler B, Buss N & Steimer JL. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clinical Pharmacokinetics 1999; 37:75-86.
18. Kilby JM, Sfakianos G, Gizzi N, Siemon-Hryczyk P, Ehrensing E, Oo C, Buss N & Saag MS. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus mini-dose ritonavir in HIV-negative adults. Antimicrobial Agents and Chemotherapy 2000; 44:2672-2678.
19. Kravcik S, Sahai J, Kerr B, Anderson R, Buss N, Seguin I, Bristw N, Farnsworth A, Salgo M, Mastrodonato-Delora P & Cameron W. Nelfinavir mesylate (NFV) increases saquinavir soft gel capsule (SQV-SGC) exposure in HIV+ patients. 4th Conference on Retroviruses and Opportunistic Infections, Washington, USA, 22-26 January 1997, Abstract 389.
20. Jorga K & Buss NE. Pharmacokinetic (PK) drug interaction with saquinavir soft gelatin capsule. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Calif., USA, 26-29 September 1999, Poster 339.
21. Johnson M, on behalf of the SPICE (NV15436) Study Group. Quadruple therapy with saquinavir soft gelatin capsules (SQV-SCG) plus nelfinavir (NFV) versus triple therapy with either SQV-SGC or NFV in patients with antiretroviral experience of high baseline viral load. 6th International Conference on Retroviruses and Opportunistic Infections. Chicago, Ill., USA, 31 January-4 February 1999, Abstract 389.
22. Buss N. Saquinavir soft gel capsule (Fortovase): pharmacokinetics and drug interactions. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, 1-5 February 1998, Abstract 354.
23. Thompson M, on behalf of the NV15355 Study Team. Activity of soft gelatin capsule formulation of saquinavir in combination with two nucleosides in treatment-naïve HIV-1 seropositive persons. 12th World AIDS Conference, Geneva, Switzerland, 28 June-3 July 1998. Poster.
24. Petersen A, Antunes F & Aratesh KN. A comparison of the long-term antiviral efficacy of BID and TID dosing of nelfinavir in combination with stavudine and lamivudine beyond 48 weeks. Seventh European Conference on Clinical Aspects and Treatment of HIV-infection, Lisbon, Portugal, 23-27 October 1999. Abstract 205.
25. AIDSLINE. Twice daily indinavir trial stopped. Treatment Update 1998; 10:3-4.
26. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ & Ruiz NM. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 team. New England Journal of Medicine 1999; 341:1865-1873.
27. Sension MG, Farthing C, Shaffer AG, Graham E, Siemon-Hryczyk P & Pilson RS. Challenges of antiretroviral treatment in transient and drug-using populations: the SUN study. AIDS Patient Care and STDs 2001; 15:129-136.
28. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ & Cooper DA. Diagnosis, prediction and natural course of HIV-1 protease inhibitor associated lipodystrophy, hyperlipidemia and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
29. Kirk O, Katzenstein TL, Gerstoft J, Mathiesen L, Nielsen H, Pedersen C & Lundgren JD. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: A randomized trial. AIDS 1999; 13:F9-F16.